Training and Resources
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® (pembrolizumab) in cervical cancer
KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) ≥1.
PD-L1 testing and CPS interpretation in cervical cancer
Please refer to Summary of Product Characteristics for full list of AEs and management.
More information about KEYTRUDA® (pembrolizumab) in cervical cancer
KEYTRUDA® (pembrolizumab) in endometrial cancer
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
KEYTRUDA® (pembrolizumab) KEYNOTE-775 clinical data presentation
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
Detecting and managing adverse events (AEs) while evaluating potential patient benefit with KEYTRUDA® (pembrolizumab) + LENVIMA® (lenvatinib)
KEYTRUDA Prescribing Information (Great Britain)
KEYTRUDA Prescribing Information (Northern Ireland)
LENVIMA Prescribing Information
[External links]
KEYConversations: Latest advancement in systemic treatment outcomes for patients with advanced and recurrent endometrial cancer post meeting report
Prescribing Information (Great Britain) &
Prescribing Information (Northern Ireland)
[External links]
More information about KEYTRUDA® (pembrolizumab) in endometrial cancer
KEYTRUDA® in combination with chemotherapy
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
